Senior Invitee Executive Named to National Health Information Technology Advisory Board

Senior Invitee Executive Named to National Health Information Technology Advisory Board

Deven McGraw for a term of 3 years from 2023 –

SAN FRANCISCO, December 19, 2022 /PRNewswire/ — Invite (NYSE: NVTA), a leading medical genetics company, announced the appointment by the United States Government Accountability Office (GAO) of Deven McGrawHead of Data Stewardship and Sharing at Invitae, National Health Information Technology Advisory Committee (HITAC).

Invitae's (NVTA) mission is to bring comprehensive genetic information into mainstream medical practice to improve the quality of healthcare for billions of people. (PRNewsFoto/Invitae Corporation)

Invitae’s (NVTA) mission is to bring comprehensive genetic information into mainstream medical practice to improve the quality of healthcare for billions of people. (PRNewsFoto/Invitae Corporation)

Established under the 21st Century Treatments Act in 2016, HITAC provides guidance to the National Health Information Technology Coordinator on policies, standards, implementation specifications and certification criteria related to the implementation of a health information technology infrastructure that advances electronic access, exchange and use of health information.

“I am honored to be appointed to HITAC to help shape national health information policy, particularly as it relates to improving access to important patient health data in an ethical manner. and transparent,” McGraw said. “Through my participation in HITAC’s 2022 Adopted Standards Working Group Subcommittee, I have already had the opportunity to advise on the existing set of ONC Adopted Standards and look forward to to continue my work with this impressive group on the Committee of the Whole. Invitee’s mission is to increase access and interoperability of consented patient health information will provide valuable perspective as we work towards the mission of improving health informatics.

McGraw’s term will begin on January 1, 2023. McGraw also sits on a subcommittee that advises the state of california on its policies and procedures relating to the data sharing framework. In his role at Invitae, McGraw is responsible for stewardship and data sharing. She co-founded and served as Chief Regulatory Officer of Ciitizen, a health technology company acquired by Invitae that aims to enable patients to collect, manage and share their medical information. Her previous experience includes serving as Deputy Director of Health Information Privacy with the U.S. Department of Health and Human Services’ Office of Civil Rights as the Acting Privacy Officer for the office of the National Coordinator for Health Informatics and as a partner with Manatt, Phelps & Phillips, LLP. McGraw received his Juris Doctor from Georgetown University Law Center and his Masters in Public Health from the Johns Hopkins Bloomberg School of Public Health.

For more information on the committee, visit HITAC website.

About Invite
Invitae is a leading medical genetics company trusted by millions of patients and their providers to provide timely genetic information made simple through digital technology. With precise, actionable answers to strengthen medical decision-making, Invitae empowers individuals and their families with powerful, personalized insights that could improve and extend their lives. Invitee’s genetic experts apply a rigorous approach to data and research, serving as the foundation of their mission: to bring comprehensive genetic information to traditional medicine to improve health care for billions of people.

To learn more, visit and follow the updates on Twitter, instagram, Facebook and LinkedIn @Invite.

Safe Harbor Statement
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the company’s mission to increase access to and interoperability of health information provided by patients. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those reported and should not be relied upon as an indication of future performance. These risks and uncertainties include, but are not limited to: the company’s loss history; the company’s ability to be competitive; the company’s inability to effectively manage growth; the company’s need to evolve its infrastructure in anticipation of demand for its testing and to increase demand for its testing; the company’s ability to use rapidly changing genetic data to interpret test results accurately and consistently; security breaches, data loss and other disruptions; the laws and regulations applicable to the company’s activity; and other risks disclosed in the company’s filings with the Securities and Exchange Commission, including the risks disclosed in the company’s quarterly report on Form 10-Q for the quarter ended September 30, 2022. These forward-looking statements speak only as of the date hereof, and Invite The Company disclaims any obligation to update these forward-looking statements.

Renee Kelley
(628) 213-3283



View original content to download multimedia:

SOURCE Invite Corporation

#Senior #Invitee #Executive #Named #National #Health #Information #Technology #Advisory #Board

Leave a Comment

Your email address will not be published. Required fields are marked *